The first market is not just where a healthtech company starts.

It is what the company proves.

Does it prove clinical interest?

Does it prove budget ownership?

Does it prove repeatable procurement?

Does it create a reference customer that matters internationally?

Tomorrow’s HealthVC newsletter breaks down Europe’s healthtech distribution problem and why market access matters as much as innovation.